DK1392348T3 - Behandling af demens og neurodegenerative sygdomme med moderate doser af LHRH antagonister - Google Patents
Behandling af demens og neurodegenerative sygdomme med moderate doser af LHRH antagonisterInfo
- Publication number
- DK1392348T3 DK1392348T3 DK02735312T DK02735312T DK1392348T3 DK 1392348 T3 DK1392348 T3 DK 1392348T3 DK 02735312 T DK02735312 T DK 02735312T DK 02735312 T DK02735312 T DK 02735312T DK 1392348 T3 DK1392348 T3 DK 1392348T3
- Authority
- DK
- Denmark
- Prior art keywords
- dementia
- treatment
- neurodegenerative diseases
- lhrh antagonists
- moderate doses
- Prior art date
Links
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title abstract 3
- 206010012289 Dementia Diseases 0.000 title abstract 2
- 230000004770 neurodegeneration Effects 0.000 title abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical group C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 abstract 1
- 229960003230 cetrorelix Drugs 0.000 abstract 1
- 108700008462 cetrorelix Proteins 0.000 abstract 1
- 239000002474 gonadorelin antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28743401P | 2001-04-30 | 2001-04-30 | |
| PCT/EP2002/004677 WO2002102401A1 (en) | 2001-04-30 | 2002-04-27 | Treatment of dementia and neurodegenerative diseases with intermediate doses of lhrh antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1392348T3 true DK1392348T3 (da) | 2008-09-29 |
Family
ID=23102886
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02735312T DK1392348T3 (da) | 2001-04-30 | 2002-04-27 | Behandling af demens og neurodegenerative sygdomme med moderate doser af LHRH antagonister |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7288517B2 (enExample) |
| EP (1) | EP1392348B1 (enExample) |
| JP (1) | JP2004529207A (enExample) |
| KR (1) | KR20040000446A (enExample) |
| CN (1) | CN1317030C (enExample) |
| AT (1) | ATE400287T1 (enExample) |
| AU (1) | AU2002310788B2 (enExample) |
| BG (1) | BG108339A (enExample) |
| BR (1) | BR0209290A (enExample) |
| CA (1) | CA2444876A1 (enExample) |
| CZ (1) | CZ20033167A3 (enExample) |
| DE (1) | DE60227507D1 (enExample) |
| DK (1) | DK1392348T3 (enExample) |
| ES (1) | ES2307760T3 (enExample) |
| HU (1) | HUP0400067A2 (enExample) |
| IL (1) | IL156777A0 (enExample) |
| MX (1) | MXPA03008666A (enExample) |
| NO (1) | NO20034322D0 (enExample) |
| NZ (1) | NZ544417A (enExample) |
| PL (1) | PL362319A1 (enExample) |
| PT (1) | PT1392348E (enExample) |
| RU (1) | RU2319501C2 (enExample) |
| SI (1) | SI1392348T1 (enExample) |
| SK (1) | SK14512003A3 (enExample) |
| UA (1) | UA80679C2 (enExample) |
| WO (1) | WO2002102401A1 (enExample) |
| ZA (1) | ZA200305326B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| US20020077327A1 (en) * | 1999-09-23 | 2002-06-20 | Neurocrine Biosciences, Inc. | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| AU7102201A (en) * | 2000-07-05 | 2002-01-14 | Yamanouchi Pharma Co Ltd | Propane-1,3-dione derivatives |
| DE10137174A1 (de) * | 2001-07-31 | 2003-02-13 | Zentaris Ag | Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität |
| EP1752452A4 (en) * | 2004-06-04 | 2010-07-14 | Astellas Pharma Inc | DERIVATIVE OF PROPANE-1, 3-DIONE OR ITS SALT |
| US20080171736A1 (en) * | 2004-12-23 | 2008-07-17 | Gregory Christopher W | Treatment of Alzheimer's Disease and Mild Cognitive impairment using GnRH-I analogs and one or more of acetylcholinesterase inhibitors and NMDA receptor antagonists |
| WO2006071274A2 (en) * | 2004-12-23 | 2006-07-06 | Voyager Pharmaceutical Corporation | Leuprolide acetate and acetylcholinesterase inhibitors or nmda receptor antagonists for the treatment of alzheimer’s disease |
| RU2404973C2 (ru) * | 2005-03-31 | 2010-11-27 | Астеллас Фарма Инк. | Производное соединение пропан-1,3-диона или его соль |
| US8642598B2 (en) * | 2006-10-21 | 2014-02-04 | Abbvie Inc. | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| WO2009039983A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| WO2009043441A1 (en) * | 2007-09-11 | 2009-04-09 | Mondobiotech Laboratories Ag | D-ala-gln-octadecyl ester as a therapeutic agent |
| EP2095818A1 (en) * | 2008-02-29 | 2009-09-02 | AEterna Zentaris GmbH | Use of LHRH antagonists at non-castrating doses |
| EP2307040B1 (en) * | 2008-05-29 | 2015-09-09 | Isr Immune System Regulation Ab | Use of gnrh and sex hormones for treating viral disease, in particular hiv/aids |
| CN103119035B (zh) | 2010-09-27 | 2015-09-30 | 雅培股份有限两合公司 | 杂环化合物和它们作为糖原合成酶激酶-3抑制剂的用途 |
| US9090592B2 (en) | 2010-12-30 | 2015-07-28 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors |
| EP3560555A1 (en) * | 2018-04-26 | 2019-10-30 | LifeArc | A composition for treating one or more estrogen related diseases |
| WO2025155903A1 (en) * | 2024-01-19 | 2025-07-24 | Temple University-Of The Commonwealth System Of Higher Education | Compositions of antioxidant translation modulators for treating neurodegenerative disorders |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
| JP2000511532A (ja) | 1996-05-20 | 2000-09-05 | メルク エンド カンパニー インコーポレーテッド | 性腺刺激ホルモン放出ホルモンのアンタゴニスト |
| DE19911771B4 (de) | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| WO2000069859A1 (en) | 1999-05-14 | 2000-11-23 | Neurocrine Biosciences, Inc. | Imidazo- and pyrrolo[1,2-a]pyrimid-4-ones as gonadotropin-releasing hormone receptor antagonists |
| CA2309395A1 (en) | 1999-06-04 | 2000-12-04 | Richard Lloyd Bowen | Methods for preventing and treating alzheimer's disease |
| ES2249302T3 (es) * | 1999-10-15 | 2006-04-01 | Neurocrine Biosciences, Inc. | Antagonistas del receptor de la hormona liberadora de gonadotropina y sus metodos de uso relacionados. |
| WO2001078780A1 (en) | 2000-04-13 | 2001-10-25 | Takeda Chemical Industries, Ltd. | Preventives/remedies for alzheimer's disease |
| AU7102201A (en) | 2000-07-05 | 2002-01-14 | Yamanouchi Pharma Co Ltd | Propane-1,3-dione derivatives |
-
2002
- 2002-04-27 AT AT02735312T patent/ATE400287T1/de not_active IP Right Cessation
- 2002-04-27 HU HU0400067A patent/HUP0400067A2/hu unknown
- 2002-04-27 PL PL36231902A patent/PL362319A1/xx not_active Application Discontinuation
- 2002-04-27 NZ NZ544417A patent/NZ544417A/en unknown
- 2002-04-27 AU AU2002310788A patent/AU2002310788B2/en not_active Ceased
- 2002-04-27 US US10/133,967 patent/US7288517B2/en not_active Expired - Fee Related
- 2002-04-27 IL IL15677702A patent/IL156777A0/xx unknown
- 2002-04-27 CZ CZ20033167A patent/CZ20033167A3/cs unknown
- 2002-04-27 PT PT02735312T patent/PT1392348E/pt unknown
- 2002-04-27 DE DE60227507T patent/DE60227507D1/de not_active Expired - Fee Related
- 2002-04-27 MX MXPA03008666A patent/MXPA03008666A/es active IP Right Grant
- 2002-04-27 JP JP2003504987A patent/JP2004529207A/ja not_active Withdrawn
- 2002-04-27 SK SK1451-2003A patent/SK14512003A3/sk unknown
- 2002-04-27 SI SI200230730T patent/SI1392348T1/sl unknown
- 2002-04-27 UA UA2003109180A patent/UA80679C2/uk unknown
- 2002-04-27 CN CNB028042964A patent/CN1317030C/zh not_active Expired - Fee Related
- 2002-04-27 BR BR0209290-5A patent/BR0209290A/pt not_active IP Right Cessation
- 2002-04-27 EP EP02735312A patent/EP1392348B1/en not_active Expired - Lifetime
- 2002-04-27 DK DK02735312T patent/DK1392348T3/da active
- 2002-04-27 KR KR10-2003-7014128A patent/KR20040000446A/ko not_active Ceased
- 2002-04-27 CA CA002444876A patent/CA2444876A1/en not_active Abandoned
- 2002-04-27 RU RU2003134949/14A patent/RU2319501C2/ru not_active IP Right Cessation
- 2002-04-27 WO PCT/EP2002/004677 patent/WO2002102401A1/en not_active Ceased
- 2002-04-27 ES ES02735312T patent/ES2307760T3/es not_active Expired - Lifetime
-
2003
- 2003-07-10 ZA ZA200305326A patent/ZA200305326B/xx unknown
- 2003-09-26 NO NO20034322A patent/NO20034322D0/no not_active Application Discontinuation
- 2003-11-10 BG BG108339A patent/BG108339A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1392348B1 (en) | 2008-07-09 |
| KR20040000446A (ko) | 2004-01-03 |
| CN1317030C (zh) | 2007-05-23 |
| CA2444876A1 (en) | 2002-12-27 |
| ATE400287T1 (de) | 2008-07-15 |
| IL156777A0 (en) | 2004-02-08 |
| JP2004529207A (ja) | 2004-09-24 |
| EP1392348A1 (en) | 2004-03-03 |
| NO20034322L (no) | 2003-09-26 |
| ZA200305326B (en) | 2003-07-30 |
| HK1072000A1 (en) | 2005-08-12 |
| MXPA03008666A (es) | 2004-10-15 |
| ES2307760T3 (es) | 2008-12-01 |
| RU2319501C2 (ru) | 2008-03-20 |
| CN1575185A (zh) | 2005-02-02 |
| WO2002102401A1 (en) | 2002-12-27 |
| NO20034322D0 (no) | 2003-09-26 |
| CZ20033167A3 (cs) | 2004-08-18 |
| DE60227507D1 (de) | 2008-08-21 |
| RU2003134949A (ru) | 2005-02-10 |
| US7288517B2 (en) | 2007-10-30 |
| US20020177556A1 (en) | 2002-11-28 |
| SK14512003A3 (sk) | 2004-08-03 |
| AU2002310788B2 (en) | 2007-04-05 |
| UA80679C2 (en) | 2007-10-25 |
| PL362319A1 (en) | 2004-10-18 |
| NZ544417A (en) | 2008-03-28 |
| SI1392348T1 (sl) | 2008-12-31 |
| HUP0400067A2 (hu) | 2004-04-28 |
| BR0209290A (pt) | 2004-07-13 |
| BG108339A (bg) | 2004-11-30 |
| PT1392348E (pt) | 2008-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20034322L (no) | Behandling av demens og neurodegenerative sykdommer med intermediate doserav LHRH-antagonister | |
| EA200201247A1 (ru) | Соединения для лечения болезни альцгеймера | |
| DK1346041T3 (da) | Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom | |
| LU92854I2 (fr) | Combinaison de rilpivirine ou une forme thérapeutique équivalente qui en dérive telle que protégé par le brevet de base, tel qu'un sel pharmaceutiquement acceptable de rilpivirine, incluant le sel chlorhydrate de rilpivirine, et ténofovir, en particulier le fumarate de ténofovir disoproxil | |
| DE60221665D1 (de) | Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten | |
| NO20022531D0 (no) | Vaksine for forebyggelse og behandling av Alzheimer og amyloidrelaterte sykdommer | |
| EP1613347A4 (en) | BETA AMYLOID PEPTIDE DETECTING HUMANIZED ANTIBODIES | |
| EA200401473A1 (ru) | Предотвращение и лечение амилоидогенного заболевания | |
| EA200602015A1 (ru) | Гуманизированные антитела, распознающие бета-амилоидный пептид | |
| DE69533174D1 (de) | Pyridopyrimidinone, chinoline und anellierte n-heterozyklen als bradykinin-antagonisten | |
| ATE302751T1 (de) | Verbindungen zur behandlung der alzheimerischen krankheit | |
| EA200400352A1 (ru) | Органолептически приемлемые распадающиеся во рту композиции | |
| DK1594833T3 (da) | 1-phenylalkancarboxylsyrederivater til behandling af neurodegenerative sygdomme | |
| EA200301223A1 (ru) | Лекарственные формы окскарбазепина | |
| DE60123238D1 (de) | Zusammensetzungen zur behandlung von autoimmunkrankheiten | |
| ATE506959T1 (de) | Verwendung von il-18 inhibitoren | |
| PA8556701A1 (es) | Derivados del 3-azabiciclo(3.1.0)hexano | |
| NO20042208L (no) | Vaginalt administrerte anti-dysrytmiske midler for behandling av bekkensmerter | |
| EA200201138A1 (ru) | Пептид, модулирующий рецептор тромбопоэтина | |
| ATE399011T1 (de) | Substituierte diketopiperazine als oxytocin- antagonisten | |
| EA200800880A1 (ru) | Комбинация росиглитазона и донепезила, предназначенная для улучшения когнитивной функции | |
| ATE277893T1 (de) | N-(2-phenyl-4-amino-butyl)-1-naphthamide als neurokinin-1 rezeptorantagonisten | |
| DK1007040T3 (da) | Anvendelsen af phanquinon til behandlingen af Alzheimers sygdom | |
| TR200103638T2 (tr) | IL-8 Reseptör antagonistleri | |
| DE60028928D1 (de) | Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt |